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Abstract
Purpose Single-slice magnetization transfer (MT) imag-
ing has shown promising results for evaluating post-
radiation fibrosis. The study aim was to evaluate the
value of multislice MT imaging to assess tumour re-
sponse after chemoradiotherapy by comparing magne-
tization transfer ratios (MTR) with histopathological
tumour regression grade (TRG).
Materials andMethods Thirty patients with locally advanced
rectal cancer (cT3-4 and/or cN2) underwent routine
restaging MRI 8 weeks post-chemoradiotherapy, including
multislice MT-sequence, covering the entire tumour bed.
Two independent readers delineated regions of interest on
MTR maps, covering all potential remaining tumour and
fibrotic areas. Mean MTR and histogram parameters (mini-
mum, maximum, median, standard deviation, skewness, kur-
tosis, and 5-30-70-95th percentiles) were calculated. Refer-
ence standard was histological TRG1-2 (good response) and
TRG3-5 (poor response).
Results 24/30 patients were male; mean age was 67.7±
10.8 years. Mean MTR rendered AUCs of 0.65
(reader1) and 0.87 (reader2) to differentiate between
TRG1-2 versus TRG3-5. Best results were obtained for
95th percentile (AUC 0.75- 0.88). Interobserver agree-
ment was moderate (ICC 0.50) for mean MTR and
good (ICC 0.80) for 95th percentile.
Conclusions MTimaging is a promising tool to assess tumour
response post-chemoradiotherapy in rectal cancer. Particular-
ly, 95th percentile results in AUCs up to 0.88 to discriminate a
good tumour response.
Key Points
• The mean MTR can differentiate between good and poor
responders after chemoradiation.
• In addition to measurement of the mean value, histogram
analyses can be beneficial.
• The histogram parameter 95th percentile can reach AUCs of
0.75–0.88.
Keywords Magnetization transfer imaging . Rectal cancer .
Response assessment . Tumour regression grade .
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Introduction
The assessment of tumour response after chemoradiotherapy
(CRT) in patients with rectal cancer is becoming increasingly
relevant. Until recently, chemoradiotherapy followed by sur-
gical resection of the tumour was the standard, irrespective of
the response to treatment [1]. However, organ-preserving
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treatments in carefully selected patients showing a clinically
complete or near-complete response are now considered po-
tential—albeit still controversial—alternatives to resection.
Alternative options include local excision for a small tumour
remnant [2] and non-operative management (Bwatch-and-
wait^ policy) in the case of a complete tumour response
[3–5]. Critical in these organ-preserving treatments is the
availability of tools to accurately select suitable patients. In
studies reported to date so far, this has been mainly done by
clinical examination and endoscopy [6]. A restaging MRI
8 weeks after chemoradiotherapy has become standard in
many centres, as MRI has proven valuable in assessing tu-
mour downsizing, identifying tumour regression from initially
invaded structures, and thereby altering the surgical approach
[7]. However, one key challenge in MRI remains the interpre-
tation of post-radiation fibrosis [8]. With morphological MRI,
it is very difficult to discriminate between fibrosis with and
without tumour remnants [9], as was illustrated in a recent
meta-analysis that reported a poor sensitivity of 19 % for
MRI in discriminating complete response (pCR) from residual
tumour [10]. Quantification of signal intensities on T2-
weighted MRI has been suggested as helpful: a greater reduc-
tion in signal intensity after chemoradiation is observed in
complete responders, with a more homogeneous signal distri-
bution compared to patients with residual tumours. Thus far,
this approach has been addressed by only a single report [11].
Various studies have reported promising results with function-
al imaging techniques such as diffusion-weighted imaging
and dynamic contrast-enhanced MRI for the detection of re-
sidual tumour after CRT [12–14], but these techniques do not
specifically target fibrosis.
Recent reports have shown that Bmagnetization transfer^
(MT) imaging may also be a helpful tool for assessing bowel
fibrosis [15–17]. MT imaging is a technique that utilizes dif-
ferences in the magnetization interaction of free ‘unbound’
water protons and macromolecular-bound protons. After an
MT pulse is applied, there is a transfer of magnetization from
free water protons towards macromolecular-bound water pro-
tons, which can only occur when macromolecular-bound wa-
ter protons are present within a given tissue. In tissues that are
rich in macromolecules (which is typically the case in fibrosis
due to the presence of collagen), the transfer of magnetiza-
tion—expressed as the Bmagnetization transfer ratio^ or
MTR—will be high. In a recent proof-of-principle study of
26 patients with rectal cancer who were treated with preop-
erative CRT, the MTR of histopathologically proven areas of
fibrosis was significantly higher than that of areas of residual
tumour, indicating a potential benefit in adding MT imaging
to a rectal cancer imaging protocol after CRT [16]. In this
report, only a single slice of the MT sequence was acquired,
which did not cover (and is therefore not representative of)
the entire tumour area. As such, it is difficult to assess the
value of MT imaging for evaluating the overall tumour
response. Moreover, only mean MTR values were assessed,
which provide a rough estimation of the MTR of a given area
of interest, but do not take into account the heterogeneity of
the tumour and fibrosis.
The aim of the current study, therefore, was to evaluate the
potential value of multislice MT imaging of the whole tumour
volume for assessing tumour response after CRT by compar-
ing the magnetization transfer ratios with the tumour regres-
sion grade (TRG) as assessed at histopathology. A second goal
was to assess the added benefit of performing histogram anal-
yses as compared to evaluation of mean MTR values alone.
Materials and Methods
Patients
This study was performed retrospectively. According to na-
tional law, institutional review board approval was not re-
quired. All patients were informed that their anonymized data
could be used for research purposes, to which none of the
study patients objected. Between November 2012 and
June 2014, all consecutive patients with locally advanced
rectal cancer were considered for inclusion. Inclusion
criteria were (1) biopsy-proven rectal adenocarcinoma,
(2) locally advanced disease (cT3/4 and/or N2) without
distant metastasis, (3) neoadjuvant chemoradiation, (4)
availability of a restaging MRI including MT sequence,
(5) resection within 2 months after restaging MRI or, in
the case of non-operative treatment and follow-up in pa-
tients with a clinical complete response, a disease-free
follow-up period of > 1 year.
MR Imaging
MR imaging was performed at 1.5 T (Ingenia, Philips Med-
ical Systems, Best, the Netherlands) using a phased array
body coil. Patients had received no bowel preparation, and
were placed in feet-first supine position. To minimize peri-
staltic movement, patients received an intravenous bolus in-
jection of 20 mg of butylscopolamine (Buscopan;
Boehringer Ingelheim BV, Ingelheim, Germany). The rou-
tine clinical MR protocol included standard T2-weighted
(T2W) fast spin-echo sequences in three planes (sagittal,
axial, and coronal). Additionally, an axial MTR sequence
was performed, with the following parameters: multislice
fast field echo, dynamic (simultaneous acquisition of images
with and without MT pulse in one sequence), interleaved
two-dimensional, TR/TE 50/4.6, 12 ° flip angle, 2 NSA,
1.17×1.47×3.00 mm voxel size, 10 slices, 300×239 mm
field of view, 256×162 matrix, receiver bandwidth
147 Hz/pixel, acquisition time 5:02 min. The MT pulse
was an on-resonance composite pulse and consisted of four
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rectangular pulses (90°-x 90°x 90°x 90°-) with a duration of
2 ms (0.5 ms for each 90° pulse) and a bandwidth of
2083 Hz. The delay between the MT pulse and the follow-
ing excitation was 3.2 ms. The axial T2-weighted and MT
sequences were angulated in identical planes perpendicular
to the (former) tumour axis as defined on sagittal MRI.
Image evaluation and calculation of magnetization
transfer ratio (MTR) parameters
Image assessment was performed on the restaging MRI rou-
tinely performed 8 weeks after completion of CRT. Magneti-
zation transfer ratio maps were generated using a freely dis-
tributed software tool (MANGO [Multi-image Analysis GUI],
version 2.6; Research Imaging Institute, University of Texas
Health Science Center, San Antonio, TX, USA). MTR maps
were generated using the following formula on a voxel-by-
voxel basis: MTR=100×(SIoff – SIon)/SIoff, where SIoff and
SIon represent the signal intensity with the MT pulse turned
off and on, respectively. Two independent readers with 6
(DMJL) and 3 years (MHM) of specific expertise in rectal
cancer imaging manually delineated free-hand regions of in-
terest (ROIs) on the MTR maps on each individual tumour-
containing slice. The corresponding T2-weighted images as
well as the primary staging MRIs were at the readers’ disposal
as an anatomical reference and for determining the primary
tumour location (Fig. 1). On every slice, the entire area of
potential residual tumour was included within the ROI, in-
cluding any potential viable tumour remnants (isointense mass
or wall thickening) and fibrosis (hypointense wall thickening).
The two readers were blinded to each other’s results and his-
topathology outcomes. Histogram analyses were performed
using in-house software, developed in the programming envi-
ronment R language [18]. The MTR measurements were
imported, and the following normalized histogram parameters
were calculated automatically: minimum, maximum, median,
standard deviation, skewness (asymmetry of distribution),
kurtosis (width of peak of distribution), and 5th, 30th, 70th,
and 95th percentiles.
Standard of reference
Histopathological assessment of the surgical resection speci-
mens served as the primary standard of reference. This was
performed according to the method described by Quirke et al.
[19]. A dedicated GI pathologist evaluated the tumour regres-
sion grade (TRG) according to the method reported by
Mandard [20]: TRG 1 (complete regression) = absence of
residual cancer and fibrosis extending to the different layers
of the bowel wall; TRG 2 = rare residual cancer cells scattered
throughout predominantly fibrosis; TRG 3 = increase in the
number of residual cancer cells but fibrosis still predominates;
TRG 4 = residual cancer outgrowing fibrosis; and TRG 5 =
absence of any regressive changes. Patients were then dichot-
omized into two categories: TRG 1–2 (good response) and
TRG 3–5 (poor response).
Fig. 1 a Axial T2-weighted MRI at primary staging, with ‘T’ indicating
the primary tumour. b Axial restaging T2-weighted MRI performed
8 weeks after chemoradiation, and c corresponding axial MTR map
showing delineation of the tumour remnant
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Statistical analyses
Statistical analyses were performed with SPSS statistical
software version 20.0 (IBM Corp., Armonk, NY, USA).
Intraclass correlation coefficients (ICCs) and Bland-Altman
plots were calculated to determine interobserver agreement
for the MTR measurements between the two readers. Re-
ceiver operator characteristic (ROC) curves were computed,
and corresponding areas under the curve (AUCs) with 95 %
confidence intervals were calculated to assess the diagnostic
performance of the various MTR histogram parameters for
discriminating between TRG1–2 and TRG3–5. The predic-
tive value of parameters was assessed by logistic regression
analyses; parameters were selected for multivariable analy-
ses when p was<0.20. For the predicted probabilities for the
combined MTR histogram parameters, AUCs with 95 %
confidence intervals were calculated.
Results
Patient and treatment characteristics
Forty-one consecutive patients were considered for inclusion.
Eleven patients were excluded for the following reasons: de-
layed surgery after CRT (n=5), mucinous tumour (n=4), and
refusal of surgery despite clinical residual tumour (n=2). The
inclusion process and reasons for exclusion are displayed in
Fig. 2. In total, 30 patients were included (24 male, 6 female;
mean age 67.7±10.8 years). Preoperative treatment consisted
of a long course of chemoradiation (28×1.8 Gy+2×825 mg/
m2/day capecitabine) in 28 patients. The remaining two pa-
tients received 5×5 Gy, with an interval of 8–10 weeks before
surgery. The median interval between the final day of radiation
and restaging MRI was 8.9 weeks (range 6.6–24.7). Eighteen
patients underwent a low anterior resection, two underwent an
abdominoperineal resection, and two underwent transanal en-
doscopic microsurgery. Histological tumour regression grades
in these patients were as follows: TRG 1 (n=4), TRG 2 (n=5),
TRG 3 (n=7), TRG 4 (n=5), and TRG 5 (n=1). Eight patients
were followed for > 1 year according to a watch-and-wait pol-
icy (median disease-free survival of 17.5 months, range 12–21
months). These patients were all considered TRG1. In total, the
dichotomized tumour regression grade was as follows: n=17
TRG1–2 and n=13 TRG3–5.
Interobserver agreement
The intraclass correlation coefficients (ICCs) between the two
readers for the mean MTR and various histogram parameters
are given in Table 1. The ICC for the mean MTR measure-
ments was 0.50 (moderate). The highest ICCs were obtained
for the maximum MTR and the 95th percentile, with an ICC
of 0.80 (good). Figure 3 displays the Bland-Altman plot for
the meanMTRmeasurements and for the 95th percentile. The
mean bias in mean MTR between the two readers was −1.79,
and limits of agreement were±5.70. For the 95th percentile,
the mean bias was −1.22 and limits of agreement were±4.67.
MTR and histogram parameters
The mean MTR was 59.6±3.4 (TRG1–2) versus 58.4±3.1
(TRG3–5) for reader 1 (p=0.33) and 62.1±1.9 (TRG1–2) ver-
sus 59.2±1.9 (TRG3–5) for reader 2 (p<0.001). Figure 4
shows the distribution in mean MTR values (averaged for the
two readers) among the tumour regression grades. The mean
95th percentile was 73.9±4.9 (TRG1–2) versus 70.9±1.8
(TRG3–5) for reader 1 (p=0.029) and 75.7±3.0 (TRG1–2)
versus 71.4±2.4 (TRG3–5) for reader 2 (p<0.001). Table 2
shows the results of the receiver operator characteristic curve
analyses for discriminating between TRG 1–2 and TRG 3–5
for the various histogram parameters as well as for the com-
bined assessment of (1) meanMTR + skewness (2) meanMTR
+ 95th percentile, (3) skewness + 95th percentile, and (4) mean
MTR + skewness + 95th percentile. The latter combinations
were derived from the logistic regression analyses. The best
single parameter for discriminating between TRG 1–2 and
TRG 3–5 was the 95th percentile for both readers (AUC 0.75
Fig. 2 CONSORT diagram of
patient recruitment and reasons
for exclusion
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for reader 1 and 0.88 for reader 2). The various combinations of
meanMTR, skewness, and 95th percentile resulted in AUCs of
0.72–0.81 for reader 1 and 0.87–0.90 for reader 2. This was not
a significant improvement compared with the 95th percentile as
a single parameter (p=0.28–1.00).Measurements of sensitivity,
specificity, positive predictive value, negative predictive value,
and overall accuracy of the 95th percentile and the various
combinations are presented in Table 3. Sensitivity and specific-
ity for diagnosing a good response were in a range of 71–77 %
and 77–92 %, respectively.
Discussion
The purpose of this study was to evaluate the potential value
of whole-tumour MT imaging to assess tumour response after
neoadjuvant chemoradiation for rectal cancer. We compared
the mean MTR and various histogram parameters derived
from the MTR between patients with a good response after
CRT (TRG 1–2) and those with a poor response (TRG 3–5).
Results showed that MT imaging of the whole tumour volume
after CRTcould predict a TRG1–2 at histology with AUCs up
to 0.88 (for the 95th percentile), thereby confirming that MTR
may be useful for assessing fibrosis.
Interestingly, the best results were obtained for the histo-
gram parameters, and in particular for the 95th percentile,
which resulted in high AUCs for both readers 1 and 2 (0.75
and 0.88, respectively). The 95th percentile represents the
value above which the highest 5 % of the MTRmeasurements
are within a given ROI. In other words, the 95th percentile
represents the most fibrotic areas within the ROI. It is antici-
pated that the 95th percentile will be higher in patients with a
good response (with predominant fibrosis) and lower in pa-
tients with a poor response. This is indeed supported by the
findings of the current study. It also confirms our secondary
hypothesis that, compared to analysis of only mean MTR,
histogram data analysis is advantageous in that it gives us
better insight into the distribution pattern of MTR and there-
fore of the heterogeneity of the tumour area. Moreover, with a
good intraclass correlation coefficient of 0.80, the 95th per-
centile appears to be more robust than mean MTR values,
which showed only a moderate ICC of 0.50. Interobserver
reproducibility may thus be a limiting factor when assessing
MTR. For the mean MTR measurements, the difference ob-
served between patients with TRG1–2 and TRG3–5 was, in
fact, smaller than the limits of agreement for the difference in
MTR measurements between the two readers as derived from
the Bland-Altman analysis. Although ICC was considerably
better for the 95th percentile, the mean difference between the
Table 1 Intraclass
correlation coefficients


















Fig. 3 Interobserver reproducibility for mean MTR measurements (a)
and 95th percentile MTR (b). Bland-Altman plot of the averaged mea-
surement of the two readers (x-axis) plotted against the difference in
measurement between the two readers (y-axis). The continuous line rep-
resents the mean absolute difference (bias) between the two readers; the
dashed lines represent the 95 % confidence intervals of the mean differ-
ence (limits of agreement)
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two response groups was still smaller than the differences in
measurements between the two readers. While this is limiting
with regard to clinical utility, it may be partially explained by
the current study methodology, in which ROI placement was
performed directly on the MTR maps (see Fig. 1), which lack
anatomical detail, making them challenging for radiologists to
interpret. Although corresponding T2-weighted images were
used for anatomical reference during the delineation process,
it may be worthwhile investigating whether it would be help-
ful to draw the ROIs and copy them from another sequence,
such as the standard T2-weighted images. A second disadvan-
tage of quantitative imaging such as MT imaging is that it can
be a somewhat incomprehensible concept for clinicians to
interpret. A simpler, qualitative approach such as an MRI-
based scoring system may be easier for clinicians to under-
stand. The Royal Marsden research group have investigated
Fig. 4 Boxplot showing the
distribution of mean MTR values
between the different TRG
subgroups. MTR values were
averaged between the two readers
Table 2 Results from the
receiver operator characteristic
curve analyses for histogram
parameters individually and in
various combinations for in
differentiating TRG1–2 from
TRG3–5
Reader 1 Reader 2
AUC 95 % CI AUC 95 % CI
Mean MTR
Mean 0.65 0.45–0.85 0.87 0.75–1.00
Histogram parameters
Min 0.67 0.47–0.87 0.72 0.53–0.91
Max 0.67 0.45–0.88 0.58 0.37–0.80
Median 0.62 0.41–0.83 0.86 0.72–0.99
SD 0.62 0.41–0.82 0.66 0.46–0.85
Skewness 0.72 0.54–0.91 0.58 0.37–0.78
Kurtosis 0.70 0.51–0.89 0.65 0.44–0.86
5th percentile 0.50 0.28–0.72 0.65 0.45–0.85
30th percentile 0.55 0.34–0.77 0.81 0.66–0.97
70th percentile 0.68 0.48–0.87 0.88 0.76–1.00
95th percentile 0.75 0.56–0.94 0.88 0.76–1.00
Combined parameters
Mean + skewness 0.72 0.54–0.91 0.87 0.75–1.00
Mean + 95th percentile 0.75 0.56–0.94 0.90 0.78–1.00
Skewness + 95th percentile 0.81 0.65–0.97 0.89 0.77–1.00
Mean + skewness + 95th percentile 0.79 0.63–0.95 0.90 0.78–1.00
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the mrTRG, an MRI-based scoring system of tumour regres-
sion grade, which is similar in construction to the pathological
Mandard model [21]. In their report, the degree of fibrosis
determined at pathology was significantly associated with
the mrTRG, albeit with moderate interobserver agreement
(0.55) [22]. To date, this qualitative approach has not been
reproduced or validated by other groups. For future studies,
it would be interesting to compare this qualitative approach
with MT imaging for the assessment of fibrosis.
The results of the current study are in line with a previous
proof-of-principle study in 26 patients in which a single
Bsample^ slice of the MT sequence was obtained after CRT. In
that study, the single-slice MTR map was correlated with a cor-
responding whole-mount histopathology section, and individual
areas of fibrosis, tumour, and the normal rectal wall were com-
pared in detail with the underlying histology. This resulted in a
significant difference in mean MTR between areas of patholog-
ically proven fibrosis and non-fibrotic areas, including residual
tumour [16]. We did not perform such a detailed whole-mount
correlation with histopathology, but evaluated the overall MTR
of the entire tumour area (obtained frommultislice MT imaging)
to discriminate between good (TRG1–2) and poor responses
(TRG3–5) to assess the value of measuring MTR from a more
clinical, patient-based perspective. Our results confirmed that
whole-tumour MTR was helpful for differentiating between re-
sponse groups (i.e. patients with varying degrees of fibrosis).
Nevertheless, MTR measurements mainly reflect an estimation
of the amount of fibrosis, and specific information regarding the
presence and extent of residual tumour cells is limited. In this
respect, it might be interesting to combine MT imaging with
other tools such as diffusion-weighted MR imaging that specif-
ically target detection of residual tumour in order to obtain a
more complete understanding of the overall tumour response.
Diffusion-weighted imaging has shown great promise in various
studies as a sensitive technique for detecting residual tumour
within post-radiation fibrosis, with AUCs in the range of 0.87–
0.93 [13, 14, 23, 24]. As such, the two techniques may be of
complementary value in assessing the effects of chemoradiother-
apy and evaluating the various aspects of treatment response.
TheMT ratios in our study are higher than typically reported
in the literature. This is likely explained by a combination of
factors. First, we used on on-resonance MT pre-pulse, since an
on-resonance pulse has been suggested to result in a more
prominent MT effect (resulting in higher MT ratios) than that
of an off-resonanceMT pulse [25, 26], which is more common-
ly reported in the current literature. Other factors that may have
contributed to the relatively highMT ratios in our study include
the use of a multislice sequence and the dynamic acquisition of
the MTsequence (simultaneous acquisition of images with and
withoutMT pulse in one sequence). The fact that variables such
as acquisition parameters can affect the MTR reveals the need
for standardization and calibration of the MT-sequence.
There are some limitations to our study design. First, the
patient group was relatively small. Second, there were some
small differences within the study group in the neoadjuvant
treatment scheme. And finally, histopathological confirmation
was not obtained in all patients. Eight patients were followed
according to a watch-and-wait protocol, with a recurrence-free
follow-up period of 12–21 months, which was considered a
surrogate endpoint for a complete response (TRG 1).
In conclusion, MT imaging is a promising tool for
assessing tumour response after neoadjuvant chemoradiation
in rectal cancer. In addition to measurement of mean MTR,
histogram data assessment (in particular the 95th percentile)
proved beneficial and resulted in high AUCs for differentiat-
ing between patients with a good and poor response. A poten-
tial limitation of MTR is the limited interobserver agreement,
which may be improved by adjusting the measurement proto-
col, an item that should be addressed by future studies.
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